Last reviewed · How we verify
Clodronate
At a glance
| Generic name | Clodronate |
|---|---|
| Also known as | Bonefos, clodronate disodium |
| Sponsor | University of Oulu |
| Target | ADP/ATP translocase 1, ADP/ATP translocase 2, ADP/ATP translocase 3 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Therapy: Hyperbaric Oxygen and PENTOCLO for Treatment of Osteoradionecrosis of the Mandible (PHASE3)
- Effect of Different Irrigation Protocols on Postoperative Endodontic Pain and Inflammation (NA)
- The PENTO Protocol in Medication-related Osteonecrosis of the Jaw (PHASE2)
- Clinical Trial to Assess Efficacy, Tolerability of Rising Doses of Clodronate in Painful Knee Osteoarthritis Patients (PHASE2, PHASE3)
- Combined Drug Therapy in Lateral Fragility Fractures of the Femur
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. (PHASE3)
- Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer (PHASE3)
- Osteoradionecrosis and PENTOCLO Protocol: Retrospective Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clodronate CI brief — competitive landscape report
- Clodronate updates RSS · CI watch RSS
- University of Oulu portfolio CI